AnapstysBio’s imsidolimab Phase III trial’s results can bring it closer to approval

On 9 October 2023, AnapstysBio made the results of a randomised Phase III clinical trial public, which included the administration of a novel inhibitor, imsidolimab, to patients with generalised pustular psoriasis (GPP) flares, demonstrating promising outcomes for the improvement of GPP flares.